Genedrive has enjoyed a remarkable week, buoyed by indications of growing commercial interest in its innovations, alongside the prospect of new investment.

The firm specializes in creating rapid molecular diagnostic tools tailored for immediate application, eliminating the need for elaborate laboratory setups.

Their premier product, the Genedrive platform, provides genetic testing results in less than an hour through a compact, battery-powered device.

These tests are particularly impactful in scenarios where quick genetic data can alter treatment strategies, such as their CYP2C19 test for stroke management and the MT-RNR1 test, which identifies newborns susceptible to antibiotic-induced hearing loss.

What sets Genedrive apart is its ability to blend molecular accuracy with practical, real-time application in urgent and resource-constrained healthcare environments.

Recently, the company shared that its Saudi Arabian distributor has entered into a memorandum of understanding with the nation’s Ministry of Health to trial their genetic testing technology within a national hearing health program.

The flagship Genedrive platform delivers genetic test results in under an hour from a portable, battery-operated device

The agreement will see the Genedrive MT-RNR1 ID Kit tested under the ‘Generations Hear’ programme, which forms part of Saudi Arabia’s Vision 2030 strategy to modernise healthcare through precision medicine and preventive care.

Then on Friday, the group said it was in talks with one of its main shareholders that could see it secure a £1 million loan. The shares have doubled over the past trading week and soared almost 300 per cent in the past month, bringing some much-needed relief to management and long-suffering investors.

Turning to the wider market, the AIM All-Share fell 4 points to 770.58 as it failed to keep pace with the FTSE 100, which rose 0.6 per cent and briefly hit a new record earlier this week.

The next biggest riser was Orcadian Energy, the North Sea explorer, which jumped 65 per cent on what dealers might call ‘nosey buying’, though others might simply call it no news. It last updated investors on its Elke and Narwhal discoveries about four months ago, so perhaps an update is due.

Last Friday’s trading update from Strategic Minerals appeared to have a long tail effect. Magnetite production in New Mexico continues to ramp up, while closer to home in Cornwall, the company is accelerating development of its tungsten, tin and copper asset. The shares ended the week 45 per cent higher.

Up more than 17 per cent, Tertiary Minerals reported that KoBold Metals, the Silicon Valley-backed exploration group, will move to the next stage of its copper exploration programme in Zambia after completing the first phase of drilling under their partnership. 

It followed this on Friday by confirming it would begin a fresh round of drilling in Zambia to expand and deepen understanding of a promising silver, copper and zinc deposit at its Mushima North project.

The week’s biggest casualty was ValiRx, which raised £1 million of fresh investment but did so by issuing stock at a steep discount to the market price. The dilution and share price drop aside, the new funding will allow it to continue its cancer research work, which it hopes will boost long-term value.

Anglesey Mining shares fell almost 40 per cent after shareholders rejected plans for a capital reorganisation, blocking access to a conditional funding deal with Alumni Capital. With 64 per cent voting against the proposal, the company now faces severe funding uncertainty and warned it may enter administration if alternative financing cannot be secured.

Alba Mineral Resources shares dropped 25 per cent after the company raised £500,000 through a discounted placing at 0.0152p a share. The funds will support work at its Clogau, Finnsbo and Motzfeldt projects. Alba also completed the first stage of acquiring a 25.5 per cent stake in the Motzfeldt Critical Metals Project in Greenland.

Finally, Helium One Global appears to be quietly making progress with its transformation from helium explorer to producer. 

On Friday, with little fanfare, it reported construction had begun at its Galactica-Pegasus project in Colorado, a key step towards first output in December.

The AIM-listed explorer holds a 50 per cent interest alongside partner Blue Star Helium, which has started building the main production pad and pipeline network. 

Helium sales are due to start late next year, with carbon dioxide output following in 2026. Broker Panmure Liberum called it ‘a key milestone’, maintaining a 3.7p target price, a significant premium to its current 0.47p share price.

For all the markets mid- and small-cap news go to www.proactiveinvestors.co.uk

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

InvestEngine

InvestEngine

Account and trading fee-free ETF investing

Trading 212

Trading 212

Free share dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you